HC Wainwright Expects Increased Earnings for Inozyme Pharma

Inozyme Pharma, Inc. (NASDAQ:INZY) – Analysts at HC Wainwright increased their FY2024 earnings per share estimates for Inozyme Pharma in a research note issued to investors on Wednesday, November 6th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($1.62) per share for the year, up from their previous estimate of ($1.77). HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Inozyme Pharma’s Q4 2024 earnings at ($0.42) EPS, FY2025 earnings at ($1.74) EPS and FY2026 earnings at ($1.89) EPS.

Several other equities research analysts have also recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target (down from $15.00) on shares of Inozyme Pharma in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research note on Wednesday. Jefferies Financial Group reissued a “buy” rating and issued a $17.00 target price (up from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Finally, Stifel Nicolaus assumed coverage on Inozyme Pharma in a report on Thursday, September 12th. They set a “buy” rating and a $16.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.71.

Inozyme Pharma Price Performance

Shares of Inozyme Pharma stock opened at $4.10 on Friday. The company has a quick ratio of 9.84, a current ratio of 9.84 and a debt-to-equity ratio of 0.48. The company has a market cap of $257.19 million, a PE ratio of -2.81 and a beta of 1.54. The business has a 50 day moving average of $5.13 and a 200 day moving average of $4.92. Inozyme Pharma has a 52 week low of $2.71 and a 52 week high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C bought a new position in shares of Inozyme Pharma in the second quarter worth about $52,000. Meeder Asset Management Inc. bought a new stake in Inozyme Pharma during the 2nd quarter valued at approximately $68,000. SG Americas Securities LLC bought a new stake in Inozyme Pharma during the 3rd quarter valued at approximately $81,000. Values First Advisors Inc. bought a new stake in Inozyme Pharma during the 2nd quarter valued at approximately $76,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Inozyme Pharma during the 2nd quarter valued at approximately $84,000. 88.30% of the stock is owned by hedge funds and other institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.